Genetics and molecular biology: Rationale for targeting high-density lipoprotein cholesterol for therapeutic intervention

Current Opinion in Lipidology

Volumn 17, Issue 5, 2006, Pages 602-605

  Mukherjee, Sagarika ^a,b  

^a PRINCE CHARLES HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6 RECEPTOR; LIPID; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; FOOD COMPOSITION; HEART ARRHYTHMIA; HUMAN; INFLAMMATION; LIFESTYLE; LIPID DIET; LIPID METABOLISM; LIPID PEROXIDATION; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SUDDEN DEATH;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION MEDIATORS; RISK FACTORS;

EID: 33748545360     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000245265.93999.ef     Document Type: Note

References (17)

1. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
3. Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol 2006; 97:372-375.
4. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116 (Suppl 6A):9S-16S.
5. Piche ME, Lemieux S, Weisnagel SJ, et al. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005; 96:92-97.
6. McMahan AC, Gidding SS, Fayad ZA, et al., for Pathobiological Determinants of Atherosclerosis in Youth Study. Risk scores predict atherosclerotic lesions in young people. Arch Intern Med 2005; 165:883-890.
7. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults Study (ARYA). Arch Intern Med 2003; 163:1787-1992.
8. Ahmed W, Orasanu G, Nehra V, et al. High density lipoprotein hydrolysis by endothelial lipase activates PPARa. Circ Res 2006; 98:490-498.
9. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106:484-490.
10. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98:1352-1364.
11. Farretti G, Bacchetti T, Negre-Salvayre A, et al. Structural modifications of HDL and functional consequences. Atherosclerosis 2006; 184:1-7.
12. Garner B, Waldeck AR, Witting PK, et al. Oxidation of high density lipoproteins II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273:6088-6095.
13. Ferretti G, Bacchetti T, Marchionni C, et al. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38:163-169.
14. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high density lipoprotein function. Diabetologia 2000; 43:312-320.
15. Suc I, Brunet S, Mitchell G, et al. Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptor, classes A and B. Br J Cell Sci 2003; 116:89-99.
16. Wood DA. JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl 5):v1-v52.
17. Duffy D, Rader D. Emerging therapies targeting high density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006; 113:1140-1150.